NEWHALL CHARLES W III 4

What Happened

• Charles W. Newhall III, a director of Supernus Pharmaceuticals (SUPN), was granted two awards of restricted stock units (RSUs) on February 18, 2026: 2,989 RSUs and 4,977 RSUs, totaling 7,966 RSUs.
• The RSUs were granted at $0.00 (standard for RSU awards); as derivative awards they have no immediate cash value recorded in the Form 4. They represent the right to receive one share of Supernus common stock per RSU upon vesting.

Key Details

• Transaction date: 2026-02-18; Grant code = A (award/acquisition); Grant price reported $0.00.
• Total RSUs granted: 2,989 + 4,977 = 7,966 RSUs.
• Vesting/settlement: Footnotes state each RSU equals one share (F1) and will be settled in common stock upon vesting on February 18, 2027 (F2).
• Filing: Form 4 filed on 2026-02-20 — appears timely (within the required two business days).
• Shares owned after transaction: Not disclosed in this filing.
• Additional footnote: F3 notes “Each option vests on February 18, 2027,” but this report records RSU grants rather than option exercises.

Context

• RSU grants are compensation awards that convert to shares only after vesting; they are not an open-market purchase or sale and do not immediately change the director’s share position until settlement.
• Such awards are common for directors and executives as part of long-term incentive pay; they should be interpreted as compensation-related grants rather than direct market bets.